At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy
In Brief
A Phase 2 clinical trial evaluating Placebo and Rapamycin for Angiofibromas and Tuberous Sclerosis. Completed, enrolled 179 participants across 10 sites in 2 countries.
Detailed Summary
The study is a multi-center prospective, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of a topically applied formulation of rapamycin to cutaneous angiofibromas in subjects with Tuberous Sclerosis Complex (TSC). Subjects will apply either the topical vehicle containing rapamycin or the topical vehicle alone nightly to their angiofibromas for six months. The primary goal of this study is to evaluate the efficacy of the topical medication for reduction of cutaneous angiofibromas in patients with TSC. The secondary goal of this study is to confirm the safety of the topical medication.
Study Details
Timeline
Interventions
Study cream is applied nightly to the affected areas on the face.
Study cream is applied nightly to the affected areas on the face. Low Dose
Study cream is applied nightly to the affected areas on the face. High Dose